Human immunodeficiency virus type I Tat protein mutant 1-37-site sequence and application thereof
A technology for human immunodeficiency and protein mutants, which can be used in applications, viral peptides, antiviral agents, etc., and can solve problems such as low antibody titers and poor cross-reactivity
Inactive Publication Date: 2013-06-05
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
The sequence and structural characteristics of the above-mentioned HIV-1 Tat molecule itself make natural Tat a candidate antigen for HIV vaccines, which still has the disadvantages of inducing immune protective antibody titers and poor cross-reactivity.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0043] Example 1: Through the construction of recombinant plasmids, prokaryotic expression and immunogenicity analysis of fusion proteins, three truncated Tat protein mutant sequences that can specifically react with HIV-1 full-length Tat proteins were obtained
[0044] 1. In vitro synthesis of the target gene
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More
Abstract
The invention relates to the technical field of biomedical engineering. HIV-1 type trans-activator of transcription (Tat) is an important regulatory protein produced at HIV-1 infection early stage. The invention aims at screening to obtain an HIV-1 type Tat protein mutant sequence with relatively stable molecular conformation and can start relatively strong immune response. The HIV-1 Tat protein mutant amino acid sequence is represented by SEQ ID NO: 2. Anti-rabbit serums of the Tat mutant protein are all subjected to specific reactions with HIV-1 full-length Tat protein, and the reactions are stronger. Therefore, the protein mutant can be used in preparing a component of an anti-HIV-infection peptide medicine, or as a candidate antigen in preparing HIV Tat vaccine.
Description
[0001] This application is a divisional application of the invention patent application submitted on March 25, 2011 with the patent application number 201110074185.7 and the invention title "Human Immunodeficiency Virus Type I Tat Protein Mutant Sequence and Its Application". technical field [0002] The invention relates to the technical field of biomedical engineering, in particular to human immunodeficiency virus type I Tat protein mutant sequence, and its application in the preparation of HIV immunogen, its application in the preparation of preventive and therapeutic HIV vaccines, and its application in the preparation of HIV detection application in the kit. Background technique [0003] Human immunodeficiency virus (Human immunodeficiency virus, HIV) is mainly transmitted through blood, sexual contact, and vertical channels from mother to child, and can cause acquired immunodeficiency syndrome (AIDS), that is, AIDS. According to the new statistics of UNAIDS at the end ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More
IPC IPC(8): C07K14/16C12N15/49C12Q1/70C12Q1/68A61K39/21A61K48/00A61P31/18G01N33/68
Inventor 曹洁张华群潘卫陈秋莉王锦红廖文婷祁培培杨界刘超何婷
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com